Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer

Introduction: Colorectal cancer is one of the most prevalent life-threatening malignant tumors with high incidence and mortality. However, the efficacy of current therapeutic regimens is very limited. Regorafenib has been approved for second- or third-line treatment of patients who are refractory to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Tao, Wu, Ruilin, Wang, Weihua, Liu, Yue, Kong, Wencheng, Yang, Bo, He, Qiaojun, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149949/
https://www.ncbi.nlm.nih.gov/pubmed/37138847
http://dx.doi.org/10.3389/fphar.2023.1136114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149949/
https://www.ncbi.nlm.nih.gov/pubmed/37138847
http://dx.doi.org/10.3389/fphar.2023.1136114

Ejemplares similares